在精神疾病中GLP-1激动剂的有效性:一个范围审查
Mohsan Ali1,2, Ayesha Ahmed1, Basim Ahmed Khan3
1King Edward Medical University, Lahore, Pakistan.
The primary care companion for CNS disorders
|June 12, 2025
概括
类似葡萄糖-1受体激动剂 (GLP-1RA) 显示出治疗抑郁症和自闭症相关疾病的前景. 然而,证据不支持它们用于精神分裂症,可卡因成或痴呆症,需要进一步研究.
科学领域:
- 神经科学是一个神经科学.
- 内分泌学 在内分泌学.
- 精神病学是一个精神病学.
背景情况:
- 葡萄糖类-1受体激动剂 (GLP-1RA) 是已确立的抗糖尿病药物.
- 新兴证据表明GLP-1RA可能具有超出代谢控制的治疗应用,包括精神疾病.
- 需要对当前证据进行全面审查,以巩固在精神病治疗中GLP-1RA的发现.
研究的目的:
- 在各种精神疾病中对GLP-1RA的影响进行范围审查.
- 为了确定GLP-1RA表现出治疗潜力的精神疾病.
- 突出需要进一步调查关于精神病学GLP-1RA的领域.
主要方法:
- 在主要的科学数据库 (PubMed, Web of Science, Scopus, ClinicalTrials.gov, PsycNet) 中进行了全面的文献搜索.
- 包括研究GLP-1RA对精神疾病影响的原始研究文章.
- 该审查综合了与有效性,缺乏有效性和不确定的结果相关的发现.
主要成果:
- GLP-1RA在治疗自闭症相关疾病和抑郁症方面表现出有效性.
- 在精神分裂症,可卡因成或痴呆症中,对神经认知或心理社会功能没有观察到显著的益处.
- 对于GLP-1RA对痴呆症焦虑和认知功能的影响,存在有限且不确定的证据.
结论:
- GLP-1RA代表了与酒精有关的疾病,抑郁症和自闭症相关的饮食行为潜在的新疗法策略.
- 目前的证据不支持使用GLP-1RA治疗精神分裂症,可卡因成或痴呆症.
- 精心设计的长期研究对于了解GLP-1RA在精神病学应用中的机制和临床实用性至关重要.
相关概念视频
01:24Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306
01:26Psychosis: Goals of Pharmacotherapy
110
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
110
01:28Psychosis and Antipsychotic Drugs: Overview
195
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
195
01:23Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
01:23Antidepressant Drugs: MAOIs and Other Agents
204
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
204
01:28Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40